Lilly to Expand Oncology Portfolio with Purchase of Loxo Oncology

Posted by ISPE Boston
On January 17, 2019

Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo for $235 per share in cash, or approximately $8.0 billion. Headquartered in Stamford, Connecticut, Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be […]

Gilead Inks Agreements with Scholar Rock and Agenus

Posted by ISPE Boston
On January 10, 2019

In in the space of two days in December, Gilead Sciences of Foster City, California announced agreements with two Massachusetts-based biotechs, the first with Scholar Rock of Cambridge and the second with Agenus of Lexington. Gilead will work with Scholar Rock to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation […]

Biogen to Partner with Local Biotechs C4T and Skyhawk on New Treatments

Posted by ISPE Boston
On January 7, 2019

Biogen has announced separate strategic collaborations with C4 Therapeutics (C4T) of Watertown and Skyhawk Therapeutics of Waltham to discover and develop potential new treatments for neurological conditions. C4T is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell. This targeted protein degradation approach […]

Atlas Venture Announces $250 Million Biotech Opportunity Fund

Posted by ISPE Boston
On January 7, 2019

Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, has announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed fundraise. With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing Atlas portfolio companies as they progress. “We are delighted and humbled by the […]

Bristol-Myers Squibb to Acquire Celgene in Deal Worth $74 Billion

Posted by ISPE Boston
On January 7, 2019

Bristol-Myers Squibb and Celgene have announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. The Boards of Directors of both companies have approved the combination. The transaction is subject to approval by Bristol-Myers […]

Entrada Launches with $59m in Venture Capital

Posted by ISPE Boston
On December 18, 2018

Entrada Therapeutics has raised $59 million in a Series A financing co-led by 5AM Ventures and MPM Capital, along with Roche Venture Fund, MRL Ventures Fund and Agent Capital. Entrada was funded and incubated within 5AM’s 4:59 Initiative via a seed investment by 5AM Ventures, Roche Venture Fund and MRLV. Entrada’s proprietary intracellular biologics platform has […]

PARP Inhibitors May Offer New Treatment Options for Cancer Patients

Posted by ISPE Boston
On December 12, 2018

PARP, or poly(ADP-ribose) polymerase, is a family of proteins that helps repair damaged DNA in cells. A PARP inhibitor may prevent cancer cells from repairing their damaged DNA, which can cause cancer cells to die. This may slow the return or progress of cancer. BRCA is a gene that is linked to increased risk for […]

GSK to Acquire TESARO for $5.1 Billion

Posted by ISPE Boston
On December 12, 2018

TESARO, an oncology-focused company based in Waltham, and GlaxoSmithKline (GSK) have announced that they have entered into a definitive agreement by which GSK will acquire TESARO for an aggregate cash consideration of approximately $5.1 billion. The proposed transaction significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. TESARO […]

New Triple-Drug Therapy from Vertex Shows Promise

Posted by ISPE Boston
On November 30, 2018

Vertex Pharmaceuticals has announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two Phase 3 studies in people with cystic fibrosis (CF). Vertex also today announced that enrollment is complete for the two Phase 3 studies of the triple combination […]

Tango Therapeutics and Gilead Sciences to Collaborate on Immuno-Oncology

Posted by ISPE Boston
On November 12, 2018

Cambridge-based Tango Therapeutics, a company focused on the discovery and development of novel cancer therapies, has announced a global strategic collaboration with Gilead Sciences to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have […]

Page 1 of 1212 3 ›»